Eiropas Savienība - latviešu - EMA (European Medicines Agency)

xbiotech germany gmbh - cilvēka igg1 monoklonāla antiviela, kas raksturīga cilvēka interleukīna-1 alfa - kolorektālie jaunveidojumi - antineoplastiski līdzekļi - Ārstēšana ar metastātisku kolorektālu vēzi.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcīnas - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. izmantojot šo vakcīnu, kas būtu saskaņā ar oficiālās rekomendācijas.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

baxter holding b.v. - insulin human (rdna) - cukura diabēts - cukura diabēts - inpremzia is indicated for the treatment of diabetes mellitus.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

pfizer limited - pneumococcal oligosaccharide serotype 18c, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14 - pneumococcal infections; immunization - vakcīnas - aktīvās imunizācijas pret slimību izraisa streptococcus pneumoniae serotipu 4, 6b, 9v, 14, 18 c, 19f un 23f (ieskaitot sepse, meningīts, pneimonija, bakterēmija un akūtu vidusauss iekaisumu) zīdaiņi un bērni vecumā no diviem mēnešiem līdz pieciem gadiem. izmantot prevenar būtu jānosaka, pamatojoties uz oficiālajām rekomendācijām, ņemot vērā ietekmi invazīvās slimības dažādās vecuma grupās, kā arī mainīgumu serotipu epidemioloģiju dažādās ģeogrāfiskās teritorijās.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

merck sharp & dohme b.v. - rotavīrusa serotips g1, serotips g2, serotips g3, serotips g4, serotips p1 - immunization; rotavirus infections - vaccines, viral vaccines - rotateq ir indicēts zīdaiņu aktīvai imunizācijai no sešu nedēļu vecās līdz 32 nedēļas, lai novērstu rotavīrusa infekcijas izraisītu gastroenterītu. rotateq ir jāizmanto, pamatojoties uz oficiālās rekomendācijas.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

amicus therapeutics europe limited - migalastat hydrochloride - fabriku slimība - migalastat - galafold ir norādīts par ilgtermiņa attieksmi pret pieaugušajiem un pusaudžiem vecumā no 16 gadiem un vecāki ar apstiprināto diagnostiku fabry slimības (α-galactosidase trūkumu) un kuriem ir grozāmi mutāciju.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

sanofi pasteur s.a. - split gripas vīrusu, inaktivēta, kas satur antigēnu*: a/california/7/2009 (h1n1)v, piemēram, celms (x-179.a)*pavairotu olas. - influenza, human; immunization; disease outbreaks - vakcīnas - gripas profilakse oficiāli paziņotajā pandēmijas situācijā. gripas vakcīna būtu jāizmanto saskaņā ar oficiālās vadlīnijas.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

pfizer europe ma eeig - pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 8, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 10a, pneumococcal polysaccharide serotype 11a, pneumococcal polysaccharide serotype 12f, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 15b, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 22f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 33f - pneimokoku infekcijas - vakcīnas - active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. skatīt nodaļas 4. 4 un 5. 1, lai iegūtu informāciju par aizsardzību pret specifiskiem pneimokoku serotipiem. apexxnar should be used in accordance with official recommendations. .

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

seqirus s.r.l.  - govju vīrusa virsmas antigēni, inaktivēti: a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - influenza vaccines - gripas profilakse oficiāli paziņotajā pandēmijas situācijā. pandēmiskās gripas vakcīna jāizmanto saskaņā ar oficiālajām vadlīnijām.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - denges - vakcīnas - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 un 4. izmantot dengvaxia būtu saskaņā ar oficiālās rekomendācijas.